Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.

Transplantation - 1 Dec 2017

Levi Charlène, Frémeaux-Bacchi Véronique, Zuber Julien, Rabant Marion, Devriese Magali, Snanoudj Renaud, Scemla Anne, Amrouche Lucile, Mejean Arnaud, Legendre Christophe, Sberro-Soussan Rebecca

Abstract excerpt

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is an orphan disease with a high rate of recurrence after kidney transplantation. However, reports of successful prevention of posttransplant aHUS recurrence with eculizumab emerged a few years ago. To further delineate its optimal use, we describe the largest series of kidney transplant recipients treated with prophylactic eculizumab. METHODS: Twelve renal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Atypical Hemolytic Uremic Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement C3

Share to Complement C5

Share to Immunosuppressive Agents

Share to Kidney Failure, Chronic

Share to Kidney Transplantation

Share to Recurrence

Source

Identifiers

PMID: 28858176
DOI: 10.1097/TP.0000000000001909

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.PMID 28858176Read ↗

Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.Semantic proximity Read ↗

Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome recurrence after kidney transplantation.Semantic proximity Read ↗

Kidney Transplant Outcomes in Patients with Atypical Hemolytic Uremic Syndrome.Semantic proximity Read ↗

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.Semantic proximity Read ↗

C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.Semantic proximity Read ↗

Successful kidney transplant with eculizumab, thymoglobulin and belatacept therapy in a highly-sensitised patient with atypical haemolytic uraemic syndrome due to factor H mutation.Semantic proximity Read ↗

Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.Semantic proximity Read ↗

Liver transplantation for aHUS: still needed in the eculizumab era?Semantic proximity Read ↗

Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.Semantic proximity Read ↗

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.Semantic proximity Read ↗

FSGS Recurrence in Adults after Renal Transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.